Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NT-202 is a protein polymer-based nanostructure drug candidate being developed by NexThera for the treatment of thrombocytopenia, including idiopathic thrombocytopenic purpura. It is classified as both a polymer and a protein drug. The precise mechanism of action has not been defined or disclosed publicly. As of the latest updates, it remains in preclinical or early research stages with no orphan drug designation and is considered a new molecular entity[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NT-202.